Project Jefferson
From Wikipedia, the free encyclopedia
Project Jefferson was a covert U.S. Defense Intelligence Agency program designed to determine if the current anthrax vaccine was effective against genetically modified bacteria. The program's legal status under the 1972 Biological Weapons Convention (BWC) is disputed.[citation needed]
The operation
Project Jefferson began in 1997[1] and was designed to reproduce a strain of genetically modified anthrax isolated by Russian scientists during the 1990s.[2] The goal was to determine whether or not the strain was resistant to the commercially available U.S. anthrax vaccine.[2]
Reportage
The project was disclosed in a September 4, 2001 article in The New York Times.[3][4] Reporters Judith Miller, Stephen Engelberg and William J. Broad collaborated to write the article.[3] It is presumed that the reporters had knowledge of the program for at least several months; shortly after the article appeared they published a book that detailed the story further.[3] The 2001 book, Germs: Biological Weapons and America's Secret War, and the article are the only publicly available sources[citation needed] detailing Project Jefferson and its sister projects, Bacchus and Clear Vision.[3]